About Somatomedin-B and thrombospondin type-1 domain-containing protein
Somatomedin-B and thrombospondin type-1 domain-containing protein (SBSPON) is a protein
from Homo sapiens identified by UniProt accession
Q8IVN8, 264 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Somatomedin-B and thrombospondin type-1 domain-containing protein |
|---|
| UniProt accession | Q8IVN8 |
|---|
| Gene | SBSPON |
|---|
| Organism | Homo sapiens |
|---|
| Length | 264 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (38)
Diseases linked to this target (Open Targets).
- FEV/FVC ratio · score 0.39
- neurodegenerative disease · score 0.34
- Crohn's disease · score 0.31
- breast adenocarcinoma · score 0.15
- acute myeloid leukemia · score 0.15
- metabolite measurement · score 0.14
- glioblastoma multiforme · score 0.12
- urinary bladder cancer · score 0.12
- diffuse plaque measurement · score 0.10
- insomnia measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IVN8-F1 | alphafold | PREDICTED | 87.30 | — |
Amino-acid sequence (264 residues)
MRTLWMALCA LSRLWPGAQA GCAEAGRCCP GRDPACFARG WRLDRVYGTC FCDQACRFTG DCCFDYDRAC PARPCFVGEW SPWSGCADQC KPTTRVRRRS VQQEPQNGGA PCPPLEERAG CLEYSTPQGQ DCGHTYVPAF ITTSAFNKER TRQATSPHWS THTEDAGYCM EFKTESLTPH CALENWPLTR WMQYLREGYT VCVDCQPPAM NSVSLRCSGD GLDSDGNQTL HWQAIGNPRC QGTWKKVRRV DQCSCPAVHS FIFI
Explore Somatomedin-B and thrombospondin type-1 domain-containing protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets